1	IN THE UNITED STATES DISTRICT COURT
2	IN AND FOR THE DISTRICT OF DELAWARE
3	NOVARTIS PHARMACEUTICALS : CIVIL ACTION
4	CORPORATION, NOVARTIS : AG, NOVARTIS PHARMA AG, :
5	NOVARTIS INTERNATIONAL : - VOLUME C - PHARMACEUTICALS LTD, and :
6	LTS LOHMANN : THERAPIE-SYSTEME AG, :
7	Plaintiffs, : :
8	vs. :
9	PAR PHARMACEUTICAL, : NO. 11-1077-RGA
10	: CONSOLIDATED Defendant. : CIVIL ACTION
12	NOVARTIS PHARMACEUTICALS : CORPORATION, NOVARTIS :
13	AG, NOVARTIS PHARMA AG, : NOVARTIS INTERNATIONAL :
14	PHARMACEUTICALS LTD, and : LTS LOHMANN :
15	THERAPIE-SYSTEME AG, : Plaintiffs :
16	: vs. :
17	WATSON LABORATORIES, :
18	<pre>INC., WATSON PHARMA, : INC., and WATSON : PHARMACEUTICALS, INC., : NO. 11-1112-RGA</pre>
19	Defendants.
20	Wilmington, Delaware Wednesday, August 28, 2013
21	8:33 o'clock, a.m.
22	= · · · · · · · · · · · · · · · · ·
23	BEFORE: HONORABLE RICHARD G. ANDREWS, U.S.D.C.J.
24	I





```
1
                    THE COURT: All right. Shall we
 2
       reconvene at 1:30?
 3
                    MR. PRUGO: Terrific idea.
 4
                    MR. FIGG: That's fine.
 5
                    THE COURT: All right. We'll
 6
       reconvene at 1:30.
       (A luncheon recess was taken.)
 8
                    THE COURT: All right. Please be
 9
       seated.
10
                    Are we ready to go?
11
                    MR. PRUGO: We are, Your Honor.
12
                    THE COURT: All right. Go ahead,
13
       Mr. Prugo.
14
                    MR. PRUGO: Plaintiffs next call to
15
       the stand Dr. Tiemessen. He's an inventor on the
16
       patents in suit and is here today to talk about
17
       the development work leading to those patents.
18
19
                      Henricus Tiemessen, having been
20
                      first duly sworn, was examined and
21
                      testified as follows:
22
23
                     -DIRECT EXAMINATION- -
24
       BY MR. PRUGO:
```



1 cooperation between Sandoz and Lohmann was put on

- 2 hold. We were waiting for internal decision.
- 3 On the one hand, we had also the
- 4 oral project going on. Those were milestones
- 5 that we awaited in order to find out where the
- 6 management wants to take the further project.
- 7 And, on the other hand, also in our
- 8 department we had prepared those to think how to
- 9 do this production of the free base. So we took
- 10 that time because we were still motivated to get
- on to prepare plans to put everything together,
- 12 plans to do what needs to be done in order to go
- on with the project as soon as we get the green
- 14 light from management.
- 15 Q. Okay. If you could turn to Tab 4 in your
- 16 witness binder. There you'll find JTX 191.
- 17 Can you identify that document for
- 18 us?
- 19 A. Yes. That is the technical development
- 20 plan, which was prepared early or first half of
- 21 1994.
- Q. And if we could turn specifically to
- 23 N0260070.
- Thank you.



```
1 There's a section five. There we
```

- 2 go.
- It's on the screen now. Technical
- 4 hurdles. Do you see that?
- 5 A. Yes.
- 6 Q. Can you explain to the Court what's
- 7 written here?
- 8 A. This is a table which we have compiled all
- 9 the technical hurdles which we could encounter
- 10 when we carry out the program. And the first is
- 11 the identification of the hurdle. The
- 12 probabilities that hurdle actually will occur.
- And the third column we have the
- impact. If this hurdle occurs, what will be the
- impact in terms of time, cost or 'termination.
- Q. All right. Thank you.
- 17 And I want to just do these one at
- 18 time. Here it states stability/quality of base.
- 19 What does that mean?
- 20 A. This refers to the drug substance, the
- 21 rivastigmine base. This refers to the stability,
- 22 the quality, as well as also the manufacturing of
- 23 the base because Sandoz had never produced a drug
- 24 substance as a liquid.



- 1 Q. And under probability, you see the number
- 2 15 percent. What does that indicate?
- 3 A. That indicates that we go back to
- 4 encounter serious problem, problem about -- 15
- 5 percent is a very low figure.
- Q. And can you describe for us what the
- 7 impact was?
- 8 A. Okay. When we would encounter this
- 9 problem, then we expect to have a delay in order
- 10 to fix this problem.
- 11 Q. Okay. And the next technical hurdle,
- 12 stability of patch.
- What is that a reference to?
- 14 A. That's referring to the -- it was the
- 15 chemical as well as the physical stability of the
- 16 patch. And that also includes the adhesion
- 17 properties, et cetera.
- 18 Q. And can you describe for the Court what
- 19 the 20 percent refers to?
- 20 A. This refers to the total of the
- 21 probability that you would have, either chemical
- 22 instability or physical instability.
- Q. Okay. Can you walk us through the
- 24 potential impact?



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

